These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17922863)

  • 21. p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation.
    Bott SR; Arya M; Kirby RS; Williamson M
    Prostate Cancer Prostatic Dis; 2005; 8(4):321-6. PubMed ID: 16276353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features.
    Sathyanarayana UG; Padar A; Suzuki M; Maruyama R; Shigematsu H; Hsieh JT; Frenkel EP; Gazdar AF
    Clin Cancer Res; 2003 Dec; 9(17):6395-400. PubMed ID: 14695140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential link between estrogen receptor-alpha gene hypomethylation and uterine fibroid formation.
    Asada H; Yamagata Y; Taketani T; Matsuoka A; Tamura H; Hattori N; Ohgane J; Hattori N; Shiota K; Sugino N
    Mol Hum Reprod; 2008 Sep; 14(9):539-45. PubMed ID: 18701604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer.
    Shabbir M; Ryten M; Thompson C; Mikhailidis D; Burnstock G
    BJU Int; 2008 Feb; 101(3):352-9. PubMed ID: 18005209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0N promoter in prostate cancer cells.
    Zhang X; Leung YK; Ho SM
    Oncogene; 2007 Nov; 26(52):7346-54. PubMed ID: 17525739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
    Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation.
    Ahmed H; Banerjee PP; Vasta GR
    Biochem Biophys Res Commun; 2007 Jun; 358(1):241-6. PubMed ID: 17481580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IGFBP7 promoter methylation and gene expression analysis in prostate cancer.
    Sullivan L; Murphy TM; Barrett C; Loftus B; Thornhill J; Lawler M; Hollywood D; Lynch T; Perry AS
    J Urol; 2012 Oct; 188(4):1354-60. PubMed ID: 22906661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HRK inactivation associated with promoter methylation and LOH in prostate cancer.
    Higuchi T; Nakamura M; Shimada K; Ishida E; Hirao K; Konishi N
    Prostate; 2008 Jan; 68(1):105-13. PubMed ID: 18008329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
    Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors.
    Hobisch A; Hittmair A; Daxenbichler G; Wille S; Radmayr C; Hobisch-Hagen P; Bartsch G; Klocker H; Culig Z
    J Pathol; 1997 Jul; 182(3):356-61. PubMed ID: 9349240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Promotor hypermethylation of E-cadherin, p16 and estrogen receptor in prostate carcinoma].
    Yao Q; He XS; Zhang JM; He J
    Zhonghua Nan Ke Xue; 2006 Jan; 12(1):28-31. PubMed ID: 16483154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
    Oh WK; Tay MH; Huang J
    Cancer; 2007 Feb; 109(3):477-86. PubMed ID: 17186531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear translocation of apoptosis inducing factor is associated with cisplatin induced apoptosis in LNCaP prostate cancer cells.
    Zhang W; Zhang C; Narayani N; Du C; Balaji KC
    Cancer Lett; 2007 Sep; 255(1):127-34. PubMed ID: 17560018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hypermethylation of estrogen receptor-alpha gene and high homocysteine in atheromatosis patients].
    Zhi Y; Huang Y; Li Z; Zhang R
    Wei Sheng Yan Jiu; 2008 May; 37(3):314-7. PubMed ID: 18646531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
    Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
    Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.
    Zon G; Barker MA; Kaur P; Groshen S; Jones LW; Imam SA; Boyd VL
    Anal Biochem; 2009 Sep; 392(2):117-25. PubMed ID: 19505431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
    Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
    Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.